PURPOSE Despite decreased screening-based detection of clinically insignificant tumors,
most diagnosed prostate cancers are still indolent, indicating a need for better strategies for …

Background DNA originating from degenerate tumour cells can be detected in the circulation
in many tumour types, where it can be used as a marker of disease burden as well as to …

Background Several systemic therapeutic options exist for metastatic castrate-sensitive
prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic …

The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs
from that of the primary tumor and is dynamic during tumor progression. The real-time and …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

PURPOSE Circulating tumor DNA (ctDNA) sequencing provides a minimally invasive
method for tumor molecular stratification. Commercial ctDNA sequencing is increasingly …

Background: Real-time knowledge of the somatic genome can influence management of
patients with metastatic castration-resistant prostate cancer (mCRPC). While routine …

Background Multiple treatments are available for metastatic castration-resistant prostate
cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and …

Background There are multiple existing and emerging therapeutic avenues for metastatic
prostate cancer, with a common denominator, which is the need for predictive biomarkers …

Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …